Compare KFFB & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KFFB | PRPO |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.5M | 32.4M |
| IPO Year | 2005 | N/A |
| Metric | KFFB | PRPO |
|---|---|---|
| Price | $4.31 | $24.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.9K | ★ 14.3K |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | $9,467,000.00 | ★ $22,800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $66.85 | ★ N/A |
| Revenue Growth | 26.65 | ★ 30.95 |
| 52 Week Low | $1.96 | $3.90 |
| 52 Week High | $4.97 | $28.50 |
| Indicator | KFFB | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 53.95 | 59.64 |
| Support Level | $4.19 | $22.50 |
| Resistance Level | $4.44 | $24.99 |
| Average True Range (ATR) | 0.23 | 2.02 |
| MACD | -0.03 | 0.10 |
| Stochastic Oscillator | 24.14 | 64.50 |
Kentucky First Federal Bancorp is a holding company. The company, through its subsidiaries, is engaged mainly in the business of accepting deposits from the general public and using such funds to originate loans secured by first mortgages on owner-occupied, residential real estate and other loans secured by real estate. Its primary products and services include Residential mortgage loans, Multi-family loans, Construction loans, and types of deposits etc. The company mainly operates in Perry, Franklin, Boyle, and Garrard and surrounding counties in Kentucky, USA.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.